Treatment of aHUS

hospital machine

Treatment of aHUS

The National aHUS service will consider patients with a potential diagnosis of aHUS for treatment with eculizumab.  These patients should be discussed with the National aHUS service as guided by our EMERGENCY REFERRAL pathway. 

The National aHUS service will consider patients with aHUS who have end-stage renal failure and may benefit from the prophylactic use of eculizumab at time of renal transplantation. 

Access to Eculizumab and Ravulizumab in England

NHS England published NICE guidance for the use of Eculizumab for treating in aHUS in January 2015. After a competitive tendering process, the NRCTC encompassing the National aHUS service based at Newcastle upon Tyne Hospitals NHS Foundation Trust was commissioned for the expert diagnosis and treatment of aHUS with Eculizumab in May 2016. The service offers comprehensive diagnostic clinical and pathological investigations and expert opinion, facilitating optimal patient management on a shared-care basis with referring clinicians and other specialist services. 

As part of the assessment of each potential new diagnosis of aHUS, we will require completion of a diagnostic checklist and a signed shared care protocol following discussion with the on-call consultant nephrologist for aHUS, contactable through the switchboard at the Newcastle upon Tyne Hospitals NHS Foundation Trust. A decision as to whether NHS England will fund Eculizumab / Ravulizumab is usually available within 24 hours. As of October 2017, to keep a complete audit trail of the process and efficiency, approval for funding of Eculizumab / Ravulizumab will only be possible via Blueteq as mandated by NHS England. 

Read more

Initial Treatment with Eculizumab

Find out more

Follow up testing in patients receiving eculizumab

Find out more

Eculizumab non-response in aHUS

Find out more
Skip to content